Lantus (insulin glargine)

17:18 EST 22nd November 2017 | BioPortfolio

LANTUS is a long- acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.  Once daily treatment for diabetes

2012 sales: $6.648 billion (€4.960 billion)

Drug maker: Sanofi

Quick Search

review and buy Lantus (insulin glargine) market research data and corporate reports here